Data Analysis for Drug Repurposing for Effective 
Alzheimer’s Medicines – Montelukast vs Fluticasone  
  
 
[STUDY_ID_REMOVED]  
  July 10, 202 3 
 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 1 1. Comparison Details 
 
a. Intended aim(s) 
 To evaluate the comparative risk of dementia onset between patients treated with Montelukast versus Fluticasone 
for asthma. 
 
b. Primary endpoint  
Incident dementia (i.e., Alzheimer’s disease, vascular dementia, senile, presenile, or unspecified dementia, or 
dementia in other diseases classified elsewhere) . 
 
2. Person responsible for implementation 
Seanna Vine  
 
3. Data Source (s) 
Medicare, 200 8-2018  
  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 2 4. Study Design Diagram s 
 

!"#$%&'()*+&,-.(./.0 1 2.3,4-5'.6& 78%.6(90):4'(& ;'<0)(5/4'.69
$

DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 4 5. Cohort Identification  
 
a. Cohort Summary 
This study will employ a new user, active comparator, observational cohort study design comparing Montelukast 
versus Fluticasone. The patients will be required to have continuous enrollment during the baseline period of 365 days 
before initiation of study drugs (cohort entry/index date). Follow -up for the outcome (dementia) differs between 
analyses. Follow-up begins the day after drug initiation (analysis 1, 3, 4 ); 180 days after drug initiation (analysis 2). 
 
b. Key details regarding cohort creation 
 
Index date: 
• Day of initiation of new Montelukast versus Fluticasone use 
 Inclusion criteria for analyses 1, 3, 4: 
• Aged > 65 years on the index date 
• 365 days enrollment in Medicare Parts A, B, and D with no HMO coverage  
• No use of Montelukast versus Fluticasone, any time prior to index date (all available lookback approach with a 
minimum of 365 days) 
• No diagnosis of dementia any time prior to and including index date • No history of nursing home admission recorded in any time prior to and including index date • At least two claims with asthma diagnosis recorded in 365 days prior to index date (ICD-9 4 93.0x, 493.1, 
493.2x, 493.8x, 493.9x or ICD-10 J44.0, J44.1, J44.9, J45.2x, J45.3x, J45.4x, J45.5x, J45.9x) 
 
Inclusion criteria for analysis 2: 
• Aged > 65 years on the index date 
• 365 days enrollment in Medicare Parts A, B, and D with no HMO coverage or 365 days registration with a 
practice contributing data to CPRD prior to index date 
• No use of Montelukast versus Fluticasone, any time prior to index date (all available lookback approach with a 
minimum of 365 days) 
• No diagnosis of dementia any time prior to and including index date 
• No history of nursing home admission recorded in any time prior to and including index date • At least two claims with asthma diagnosis recorded in 365 days prior to index date (ICD -9 493.0x, 493.1, 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 5 493.2x, 493.8x, 493.9x or ICD-10 J44.0, J44.1, J44.9, J45.2x, J45.3x, J45.4x, J45.5x, J45.9x) 
• 180-day continuous use of Montelukast versus Fluticasone starting on the  index date 
 
 
c. Flowchart of the study cohort assembly 
 
  Less Excluded Patients  Remaining Patients 
All patients   23,466,175 
Did not meet cohort entry criteria -21,749,739 1,716,436 
Excluded due to insufficient enrollment -1,010,844 705,592 
Excluded based on Dementia Exclusion -113,159 592,433 
Excluded based on Nursing Home Admission -62,588 529,845 
Excluded based on Peripheral artery disease 
Diagnosis -454,167 75,678 
Excluded anyone aged <65 at index -24,145 51,533 
Patients in Montelukast group   12,575 
Patients in Fluticasone group   38,958 
Final cohort   51,533 
  
 
  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 6 6. Variables  
 
a. Exposure-related variables:  
 
Study drug:  
The study exposure of interest is initiation of Montelukast 
Comparator: 
Fluticasone 
 
b. Covariates: 
 
Demographics  
Age Region  
Gender  Calendar year of index date  
Race Low income subsidy 
  
Dementia risk factors  
Diabetes  Depression 
Obesity  Anxiety  
Hypertension  Bipolar disorder  
Coronary artery disease Schizophrenia 
 
Markers for healthy behavior, frailty, healthcare use  
Smoking  Number of outpatient visits  
Mammography Number of hospitalizations 
Colonoscopy  Number of serum creatinine tests ordered  
Fecal occult blood test  Composite frailty score  
Influenza vaccination Number of C-reactive protein tests ordered 
Pneumococcal vaccination  Osteoporosis  
Herpes zoster vaccination Fractures 
Bone mineral density test  Falls  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 7 Number of distinct generic agents Use of supplemental oxygen 
Number of emergency room visits  Combined comorbidity score  
 
Other Asthma treatments and Asthma severity indicators 
Respiratory failure  LABA  
Asthma exacerbation SABA 
Tuberculosis SAMA 
Lung Cancer LAMA 
Bronchiectasis ICS (excluding Fluticasone) 
Sarcoidosis Omalizumab, Mepolizumab, Reslizumab, 
Benralizumab, Dupilumab  
Pulmonary Hypertension Leukotriene receptor antagonist (excluding 
Montelukast)  
Interstitial lung disease, lung fibrosis, ARDS Number of Pulmonologist visits 
Acute Upper/ Lower Respiratory Tract infection Pulmonary function test 
Pneumonia Antibiotics  
Corticosteroids  
 
Comedication use 
Lithium  Diuretics  
Anti-epileptic mood stabilizers Nitrates 
Anti-epileptics (other than mood stabilizers) Lipid lowering drugs 
Atypical antipsychotics  Non-insulin diabetes medications  
Benzodiazepines Insulin 
Serotonin -norepinephrine reuptake Inhibitors  Antidepressants  
Selective serotonin reuptake inhibitors Angiotensin II receptor blockers (ARBs) 
Tricyclic antidepressants (TCAs)  Angiotensin converting enzyme inhibitors (ACEi)  
Typical antipsychotics Calcium channel blockers 
Anticoagulants Beta blockers 
Antiplatelet agents  Disease -modifying antirheumatic drugs (DMARDs)  
 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 8 Comorbid conditions  
Atrial fibrillation  Ischemic heart disease  
Coronary artery disease Chronic obstructive pulmonary disease 
Heart failure  Malignancy  
Stroke or transient ischemic attack Drug or alcohol abuse or dependence 
Peripheral vascular disease  Venous thromboembolism  
Hyperlipidemia  Chronic liver disease   
Renal dysfunction Rheumatoid Arthritis 
 
ICD-9, ICD -10, HCPCS, and NDC codes used to define the covariates listed above are available in Appendix A.  
 
c. Outcome variables and study follow-up:  
 
• Primary outcome: incident dementia, i.e., Alzheimer’s disease, vascular dementia, senile, presenile, or 
unspecified dementia, or dementia in other diseases classified elsewhere. Outcome will be defined by 1 inpatient 
claim or 2 outpatient claims in analysis 1, 2, 3. In analysis 4, the outcome will be defined by 1 inpatient or 1 
outpatient claims and 1 prescription claim for a symptomatic treatment [donepezil, galantamine, rivastigmine, and 
memantine] within 6 months of each other with outcome date assigned to second event in the sequence.  
• Secondary outcomes: Individual component:  
Alzheimer’s disease  
Condition  ICD-9 and ICD -10 codes  
Alzheimer’s disease 331.0*, F00*, G30*  
Vascular dementia  290.4*, F01*  
Senile, presenile, or unspecified dementia 290.0*, 290.1*. 290.3*, 797*, F03*  
Dementia in other diseases classified elsewhere 331.1*, 331.2*, 331.7*, 294.1*, F02*  
 
For analysis 1,3, and 4  the follow -up will start the day after initiation of Montelukast and Fluticasone and will continue 
until the earliest date of the following events: 
• The first occurrence of the outcome of interest  
• The date of end of continuous registration in the database, • End of the study period, 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 9 • Measured death event occurs, 
• The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug 
(Montelukast and Fluticasone) plus a defined grace period (i.e., 90 days after the end of the last prescription’s 
days’ supply in main analyses). 
 
For analysis 2, the follow-up will start 180 days after initiation of Montelukast and Fluticasone and will continue until the 
earliest date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, • End of the study period, 
• Measured death event occurs, 
• Maximum allowed follow-up time (1095 days) reached  
  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 10 7. Propensity score analysis   
We will use a propensity-score (PS)1-based approach to account for measured confounding in this study. The PS 
will be calculated as the predicted probability of initiating the exposure of interest (i.e., the repurposing candidate) 
versus the reference drug conditional on baseline covariates using multivariable logistic regression constructed 
separately in each data source. On average, patients with similar PSs have similar distribution of po tential 
confounders used to estimate the PS. Therefore, analyses conditioned on the PS provide effect estimates that are free from measured confounding. For all our analyses, initiators of each exposure of interest will be matched with 
initiators of the reference exposure based on their PS within each data source.
2 Pair matching will be conducted 
using a nearest-neighbor algorithm, which seeks to minimize the distance between propensity scores in each pair of treated and reference patients,
3 and a caliper of 0.025 on the natural scale of the PS will be used to ensure 
similarity between the matched patients.4  
 
We report multiple diagnostics for PS analysis in this protocol. First, the PS distributional overlap is provided 
between two groups before and after matching to ensure comparability of these groups.5 Next, balance in each 
individual covariate between two treatment groups is reported using standardized differences.6 
 
 
  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 11 8. Table for covariate balance 
  Unmatched  PS-Matched 
Variable  Montelukast Fluticasone  St. Diff  Montelukast Fluticasone  St. Diff  
  (N = 12,575) (N = 38,958)    (N = 12,572)  (N = 12,572)    
Demographics             
 Age, mean (SD)  72.8 (6.1) 73.3 (6.4) -8.20 72.8 (6.1)  72.8 (6.1)  -0.30 
 Gender, n (%)              
 Male  3694 (29.4)  12706 (32.6)  -7.00 3694 (29.4)  3764 (29.9)  -1.20 
 Female  8881 (70.6)  26252 (67.4)  7.00 8878 (70.6)  8808 (70.1)  1.20 
 Race, n (%)              
 White  10614 (84.4)  33028 (84.8)  -1.00 10613 (84.4)  10650 (84.7)  -0.80 
 Black  831 (6.6)  3055 (7.8)  -4.80 831 (6.6)  881 (7)  -1.60 
 Hispanic  218 (1.7)  639 (1.6) 0.70 218 (1.7)  203 (1.6)  0.90 
Other 912 (7.3)  2236 (5.7)  6.10 910 (7.2)  838 (6.7)  2.30 
 Region, n (%)              
 Northeast; n (%)  2271 (18.1)  8670 (22.3)  ##### 2271 (18.1)  2335 (18.6)  -1.30 
 South; n (%)  5310 (42.2)  13528 (34.7)  15.50 5307 (42.2)  5179 (41.2)  2.10 
 Midwest; n (%)  2498 (19.9)  8288 (21.3)  -3.50 2498 (19.9)  2546 (20.3)  -1.00 
 West; n (%)  2484 (19.8)  8431 (21.6)  -4.70 2484 (19.8)  2501 (19.9)  -0.30 
 Other; n (%)  12 (0.1)  41 (0.1)  -0.30 12 (0.1)  11 (0.1)  0.30 
Calendar year of index date, n (%)              
2014 3143 (25)  10567 (27.1)  -4.90 3142 (25)  3037 (24.2)  1.90 
2015 2585 (20.6)  8299 (21.3)  -1.80 2585 (20.6)  2519 (20)  1.30 
2016 2396 (19.1)  7305 (18.8)  0.80 2394 (19)  2425 (19.3)  -0.60 
2017 2330 (18.5) 6986 (17.9)  1.50 2330 (18.5)  2408 (19.2)  -1.60 
2018 2121 (16.9)  5801 (14.9)  5.40 2121 (16.9)  2183 (17.4)  -1.30 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 12 Low income subsidy, n (%) 1824 (14.5)  6953 (17.8)  -9.10 1823 (14.5)  1859 (14.8)  -0.80 
Dementia risk factors, n (%)              
Diabetes  4101 (32.6)  13257 (34)  -3.00 4098 (32.6)  4087 (32.5)  0.20 
Obesity 2804 (22.3)  9138 (23.5)  -2.80 2804 (22.3)  2808 (22.3)  -0.10 
Coronary artery disease  3338 (26.5)  11429 (29.3)  -6.20 3338 (26.6)  3264 (26)  1.30 
Hypertension  9870 (78.5)  30962 (79.5) -2.40 9867 (78.5)  9909 (78.8)  -0.80 
Depression  2029 (16.1)  6989 (17.9)  -4.80 2029 (16.1)  2013 (16)  0.30 
Anxiety  2235 (17.8)  6921 (17.8)  0.00 2235 (17.8)  2234 (17.8)  0.00 
Bipolar disorder  126 (1)  555 (1.4)  -3.90 126 (1)  120 (1)  0.50 
Schizophrenia  8 (0.1)  70 (0.2)  -3.30 8 (0.1)  3 (0)  1.90 
Markers for healthy behavior, frailty, 
healthcare use              
Smoking, n (%)  2803 (22.3)  10651 (27.3)  ##### 2803 (22.3)  2833 (22.5)  -0.60 
Mammography, n (%)  4285 (34.1)  12152 (31.2)  6.20 4283 (34.1)  4262 (33.9)  0.40 
Colonoscopy, n (%)  1465 (11.7)  4797 (12.3)  -2.00 1464 (11.6)  1465 (11.7)  0.00 
Fecal occult blood test, n (%)  1172 (9.3)  3374 (8.7)  2.30 1172 (9.3)  1172 (9.3)  0.00 
Influenza vaccination, n (%)  8417 (66.9)  26819 (68.8)  -4.10 8416 (66.9)  8463 (67.3)  -0.80 
Herpes zoster vaccination, n (%)  3 (0)  11 (0)  -0.30 3 (0)  2 (0)  0.60 
Pneumococcal vaccination, n (%)  5584 (44.4)  17347 (44.5)  -0.20 5583 (44.4)  5680 (45.2)  -1.60 
Bone mineral density test, n (%)  1743 (13.9)  5139 (13.2) 2.00 1743 (13.9)  1732 (13.8)  0.30 
Number of distinct prescriptions, mean 
(SD) 12.3 (5.8) 12.5 (5.8) -2.30 12.3 (5.8)  12.2 (5.7)  2.00 
Number of emergency room visits, mean 
(SD) 0.7 (1.4) 0.8 (1.6) -8.80 0.7 (1.4) 0.7 (1.2) 1.20 
Number of outpatient visits, mean (SD)  12.5 (8.4) 12.4 (8.6) 1.10 12.5 (8.4)  12.5 (8.6)  0.90 
Number of hospitalizations, mean (SD)  0.2 (0.6) 0.2 (0.6) -6.60 0.2 (0.6) 0.2 (0.5) 1.40 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 13 Number of C -reactive protein tests 
ordered, mean (SD)  0.2 (0.8) 0.2 (0.9) -1.20 0.2 (0.8) 0.2 (0.8) 0.40 
Number of serum creatinine tests 
ordered, mean (SD)  0.9 (1.6) 1.1 (2)  ##### 0.9 (1.6) 0.9 (1.5) 1.60 
Composite frailty score, mean (SD)  0.2 (0.1) 0.2 (0.1) ##### 0.2 (0.1) 0.2 (0.1) 1.40 
Osteoporosis, n (%)  1911 (15.2) 5814 (14.9)  0.80 1911 (15.2)  1912 (15.2)  0.00 
Fractures, n (%)  877 (7)  2787 (7.2)  -0.70 877 (7)  893 (7.1)  -0.50 
Falls, n (%) 641 (5.1)  2326 (6)  -3.80 641 (5.1)  656 (5.2)  -0.50 
Use of supplemental oxygen, n (%)  260 (2.1)  1091 (2.8)  -4.80 260 (2.1) 279 (2.2)  -1.00 
Combined comorbidity score, mean (SD)  2.2 (2.2) 2.4 (2.4) ##### 2.2 (2.2) 2.2 (2.2) 0.50 
Comedication use, n (%)              
Lithium  17 (0.1)  50 (0.1)  0.20 17 (0.1)  12 (0.1)  1.20 
Anti-epileptic mood stabilizers  142 (1.1)  562 (1.4) -2.80 142 (1.1)  149 (1.2)  -0.50 
Anti-epileptics (other than mood 
stabilizers) 1839 (14.6)  6087 (15.6)  -2.80 1837 (14.6)  1778 (14.1)  1.30 
Atypical antipsychotics 170 (1.4)  719 (1.8)  -3.90 170 (1.4)  158 (1.3)  0.80 
Benzodiazepines  2537 (20.2)  7878 (20.2)  -0.10 2537 (20.2)  2523 (20.1)  0.30 
Serotonin -norepinephrine reuptake 
inhibitors  715 (5.7)  2343 (6)  -1.40 715 (5.7)  721 (5.7)  -0.20 
Selective serotonin reuptake inhibitors  2265 (18)  7367 (18.9)  -2.30 2265 (18)  2205 (17.5)  1.20 
Tricyclic antidepressants (TCAs)  434 (3.5)  1548 (4)  -2.80 434 (3.5)  425 (3.4)  0.40 
Typical antipsychotics  20 (0.2)  105 (0.3)  -2.40 20 (0.2)  24 (0.2)  -0.80 
Anticoagulants  1163 (9.2)  4342 (11.1)  -6.30 1163 (9.3)  1217 (9.7)  -1.50 
Antiplatelet agents  947 (7.5) 3416 (8.8)  -4.50 947 (7.5)  916 (7.3)  0.90 
Nitrates  915 (7.3)  3131 (8)  -2.90 915 (7.3)  881 (7)  1.10 
Lipid lowering drugs  6790 (54)  22232 (57.1)  -6.20 6789 (54)  6819 (54.2)  -0.50 
Non-insulin diabetes medications  2391 (19)  7537 (19.3)  -0.80 2388 (19) 2415 (19.2)  -0.50 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 14 Insulin 725 (5.8)  2740 (7)  -5.20 725 (5.8)  705 (5.6)  0.70 
Antidepressants  3634 (28.9)  11842 (30.4)  -3.30 3634 (28.9)  3557 (28.3)  1.40 
Angiotensin converting enzyme 
inhibitors (ACEi)  3269 (26)  10938 (28.1)  -4.70 3268 (26)  3300 (26.2) -0.60 
Angiotensin II receptor blockers (ARBs) 3599 (28.6)  10554 (27.1)  3.40 3598 (28.6)  3563 (28.3)  0.60 
Beta blockers  4312 (34.3)  14499 (37.2)  -6.10 4312 (34.3)  4274 (34)  0.60 
Calcium channel blockers  3182 (25.3)  10328 (26.5)  -2.80 3181 (25.3) 3192 (25.4)  -0.20 
Disease -modifying antirheumatic drugs 
(DMARDs) 457 (3.6)  1522 (3.9)  -1.40 457 (3.6)  452 (3.6)  0.20 
Diuretics 5260 (41.8)  17028 (43.7)  -3.80 5259 (41.8)  5306 (42.2)  -0.80 
Biologics (Omalizumab, Mepolizumab, 
Reslizumab, Benralizumab, Dupilumab)  89 (0.7)  218 (0.6)  1.90 89 (0.7)  77 (0.6)  1.20 
Comorbid conditions, n (%)              
Atrial fibrillation  1527 (12.1)  5492 (14.1)  -5.80 1527 (12.1)  1543 (12.3)  -0.40 
Heart failure  1397 (11.1)  5145 (13.2)  -6.40 1397 (11.1)  1352 (10.8)  1.10 
Stroke or transient ischemic attack  858 (6.8)  3209 (8.2)  -5.40 858 (6.8)  867 (6.9)  -0.30 
Peripheral vascular disease  1056 (8.4)  3915 (10)  -5.70 1055 (8.4)  1055 (8.4)  0.00 
Hyperlipidemia  8900 (70.8)  27637 (70.9)  -0.40 8898 (70.8)  8820 (70.2)  1.40 
Renal dysfunction  1706 (13.6)  6279 (16.1)  -7.20 1705 (13.6)  1704 (13.6)  0.00 
Chronic liver disease  810 (6.4)  2628 (6.7)  -1.20 809 (6.4)  807 (6.4)  0.10 
Ischemic heart disease 3250 (25.8)  11107 (28.5)  -6.00 3250 (25.9)  3170 (25.2)  1.50 
Chronic obstructive pulmonary disease  5222 (41.5)  16890 (43.4)  -3.70 5220 (41.5)  5213 (41.5)  0.10 
Malignancy  3369 (26.8)  11073 (28.4)  -3.70 3369 (26.8)  3411 (27.1)  -0.80 
Drug or alcohol abuse or dependence  944 (7.5)  4336 (11.1)  ##### 944 (7.5)  936 (7.4)  0.20 
Venous thromboembolism  425 (3.4)  1565 (4)  -3.40 425 (3.4)  423 (3.4)  0.10 
Rheumatoid Arthritis  595 (4.7)  1994 (5.1)  -1.80 595 (4.7)  592 (4.7)  0.10 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 15 Other Asthma treatments and Asthma 
severity indicators              
Asthma exacerbation, n (%)  213 (1.7)  478 (1.2)  3.90 211 (1.7)  174 (1.4)  2.40 
Bronchiectasis, n (%) 347 (2.8)  1006 (2.6)  1.10 346 (2.8)  357 (2.8)  -0.50 
Interstitial lung disease, lung fibrosis, 
ARDS, n (%) 1220 (9.7)  3941 (10.1)  -1.40 1219 (9.7)  1205 (9.6)  0.40 
Lung Cancer, n (%)  144 (1.1)  674 (1.7)  -4.90 144 (1.1)  137 (1.1)  0.50 
Pneumonia, n (%)  694 (5.5)  2455 (6.3)  -3.30 693 (5.5)  670 (5.3)  0.80 
Pulmonary Hypertension, n (%)  194 (1.5) 691 (1.8)  -1.80 194 (1.5)  182 (1.4)  0.80 
Respiratory failure, n (%) 723 (5.7)  2725 (7)  -5.10 722 (5.7)  704 (5.6)  0.60 
Sarcoidosis, n (%)  60 (0.5)  259 (0.7)  -2.50 60 (0.5)  68 (0.5)  -0.90 
Tuberculosis, n (%) 2157 (17.2)  7552 (19.4)  -5.80 2155 (17.1) 2177 (17.3)  -0.50 
Acute Upper/ Lower Respiratory Tract 
infection, n (%)  4789 (38.1)  14315 (36.7)  2.80 4788 (38.1)  4850 (38.6)  -1.00 
Pulmonary function test, n (%)  4989 (39.7)  13566 (34.8)  10.00 4988 (39.7)  4943 (39.3)  0.70 
Number of Pulmonologist visits, mean 
(SD) 1.1 (2.4) 1 (2.5)  3.50 1.1 (2.4) 1.1 (2.5) 0.90 
Antibiotics, n (%)  9638 (76.6)  29724 (76.3)  0.80 9636 (76.6)  9601 (76.4)  0.70 
Corticosteroids, n (%)  6750 (53.7)  18540 (47.6)  12.20 6748 (53.7)  6551 (52.1)  3.10 
ICS (excluding Fluticasone), n (%) 3647 (29)  8369 (21.5)  17.40 3644 (29)  3386 (26.9)  4.60 
LAMA, n (%) 884 (7)  3315 (8.5)  -5.50 884 (7)  883 (7)  0.00 
LABA, n (%) 2532 (20.1)  12953 (33.2)  ##### 2532 (20.1)  2143 (17)  8.00 
Leukotriene receptor antagonist 
(excluding Montelukast), n (%) 93 (0.7)  150 (0.4)  4.70 91 (0.7)  68 (0.5)  2.30 
SABA, n (%)  6687 (53.2)  21764 (55.9)  -5.40 6684 (53.2)  6657 (53)  0.40 
SAMA, n (%)  656 (5.2)  2193 (5.6)  -1.80 656 (5.2)  629 (5)  1.00 
 
 
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 16 9. Statistical analysis plans  
Incidence rates for the outcome will be estimated for the treatment and reference groups before and after PS 
matching. The competing risk of death could be of concern for the current set of analyses if mortality is frequent 
among patients included in the cohort and if differences in the risk of mortality between treatment and reference 
groups are substantial. In the PS-matched sample, we will use cause-specific hazard models7 to provide hazard 
ratios averaged over the entire follow-up period as well as interval specific hazard ratios (1, 2, and 3 years) for the association between the treatment of interest and risk of ADRD after considering all-cause mortality as a competing 
event. Pre-specified subgroup analyses will be conducted based on age, sex, and baseline cardiovascular disease.  
 
  
DREAM study protocol  - Comparison 10 Montelukast vs Fluticasone 
 
 17 10. References 
 
1. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. 
Biometrika. 1983;70(1):41-55. 
2. Rassen JA, Avorn J, Schneeweiss S. Multivariate-adjusted pharmacoepidemiologic analyses of c onfidential 
information pooled from multiple health care utilization databases. Pharmacoepidemiology and drug safety. 
2010;19(8):848-857.  
3. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching 
in cohort studies. Pharmacoepidemiol Drug Saf. May 2012;21 Suppl 2:69-80. 
4. Austin PC. Some Methods of Propensity-Score Matching had Superior Performance to Others: Results of an 
Empirical Investigation and Monte Carlo simulations. Biometrical Journal. 2009;51(1): 171-184. 
5. AM Walker AM, Patrick A, Lauer M, et al. Tool for Assessing the Feasibility of Comparative Effectiveness 
Research. Comp Effect Res 2013;3:11 -20. 
6. Franklin JM, Rassen JA, Ackermann D, Bartels DB, Schneeweiss S. Metrics for covariate balance in cohort studies 
of causal effects. Statistics in medicine. May 10 2014;33(10):1685-1699.  
7. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. 
Circulation. 2016;133(6):601-609.  
 
 